Trials / Completed
CompletedNCT00673205
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
A Randomized, Double-Blind, Parallel-Group Trial Comparing Bicalutamide (Casodex) 150mg Once Daily With Placebo in Patients With Non-metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,588 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bicalutamide | 150mg p.o. daily |
| DRUG | Placebo |
Timeline
- Start date
- 1995-09-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2008-05-07
- Last updated
- 2010-12-10
Locations
128 sites across 16 countries: Australia, Austria, Belgium, Czechia, Germany, Hungary, Ireland, Israel, Italy, Mexico, Netherlands, Poland, Portugal, South Africa, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00673205. Inclusion in this directory is not an endorsement.